(409) A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy

NYX-2925, a novel small-molecule modulator of the N-methyl-D-aspartate receptor (NMDAR), was evaluated in a randomized, double-blind, placebo-controlled study, in which 302 subjects with painful DPN received daily oral doses of placebo or NYX-2925 at 10mg, 50mg, or 200mg for four weeks (NCT03219320). This first-in-patient study was conducted across 35 U.S.-based sites and subjects were randomized in a 1:1:1:1 ratio. Average pain intensity was collected using the 11-point Numerical Rating Scale and subjects were assessed for randomization eligibility using a proprietary algorithm employed to improve assay sensitivity.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research